Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines

被引:23
作者
Drummond, F. J. [1 ]
Carsin, A. -E. [1 ]
Sharp, L. [1 ]
Comber, H. [1 ]
机构
[1] Natl Canc Registry, Cork, Ireland
关键词
PSA; Prostate specific antigen; Prostate cancer; Incidence; Mortality; Screening; Guidelines; CANCER INCIDENCE; SCREENING-TEST; UNITED-STATES; PSA; MEN; MORTALITY; RISK; OVERDIAGNOSIS; PATTERNS; INTERVAL;
D O I
10.1007/s11845-009-0376-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Prostate specific antigen (PSA) testing is associated with increased prostate cancer (PCa) incidence. Ireland has no national guidelines on PCa screening and had the highest PCa incidence in Europe, 2006. Aims To investigate trends in PSA testing in Ireland. Methods Data on PSA tests, 1994-2005, was collated. Results Age-standardised rates of PSA testing increased 39 and 25% annually in men <50 and >= 50 years, respectively. Most tests were performed in men 50-69 years; 26 and 22% were performed in men <50 and >= 70 years, respectively. Baseline PSA tests peaked in 2004, at 16% of men. 83% of baseline tests were <4.0 ng/ml. Repeat testing increased with age and PSA level (P < 0.001); men <50 years and with levels < 4.0 ng/ml had >1 tests in <21 months. PCa incidence increased 9% annually, 1994-2005. Conclusions Uptake of PSA testing was rapid: increased use was simultaneous with increased PCa incidence. National guidelines are needed to manage this important public health issue.
引用
收藏
页码:43 / 49
页数:7
相关论文
共 42 条
[1]   Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].
Andriole, Gerald L. ;
Grubb, Robert L., III ;
Buys, Saundra S. ;
Chia, David ;
Church, Timothy R. ;
Fouad, Mona N. ;
Gelmann, Edward P. ;
Kvale, Paul A. ;
Reding, Douglas J. ;
Weissfeld, Joel L. ;
Yokochi, Lance A. ;
Crawford, E. David ;
O'Brien, Barbara ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hayes, Richard B. ;
Kramer, Barnett S. ;
Izmirlian, Grant ;
Miller, Anthony B. ;
Pinsky, Paul F. ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319
[2]  
[Anonymous], 2000, ONCOLOGY-BASEL, V14, P267
[3]   Individualized screening interval for prostate cancer based on prostate-specific antigen level - Results of a prospective, randomized, population-based study [J].
Aus, G ;
Damber, JE ;
Khatami, A ;
Lilja, H ;
Stranne, J ;
Hugosson, J .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (16) :1857-1861
[4]   Rising incidence of prostate cancer in Scotland: increased risk or increased detection? [J].
Brewster, DH ;
Fraser, LA ;
Harris, V ;
Black, RJ .
BJU INTERNATIONAL, 2000, 85 (04) :463-472
[5]   Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study [J].
Carlsson, Sigrid ;
Aus, Gunnar ;
Wessman, Catrin ;
Hugosson, Jonas .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (14) :2109-2116
[6]  
CARSIN AE, PSA TESTING IN PRESS
[7]  
Colditz GA, 2008, J PUBLIC HEALTH MAN, V14, P144, DOI 10.1097/01.PHH.0000311892.73078.8b
[8]   Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study [J].
Collin, Simon M. ;
Martin, Richard M. ;
Metcalfe, Chris ;
Gunnell, David ;
CAlbertsen, Peter ;
Neal, David ;
Hamdy, Freddie ;
Stephens, Peter ;
Lane, J. Athene ;
Moore, Rollo ;
Donovan, Jenny .
LANCET ONCOLOGY, 2008, 9 (05) :445-452
[9]  
COMBER H, TRENDS IRISH CANC IN
[10]   Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: Diagnosis is dependent on the intensity of investigation [J].
Connolly, David ;
Black, Amanda ;
Gavin, Anna ;
Keane, Patrick F. ;
Murray, Liam J. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (02) :271-278